immune responses – Page 75 – Communicable Diseases Research

Immunological Biomarkers of Fatal COVID-19: A Study of 868 Patients

치명적인 COVID-19의 면역학적 바이오마커: 868명의 환자에 대한 연구

Immunology

Published on 2021-05-032022-09-11
Journal: Frontiers in Immunology [Category] SARS, 바이오마커,

SARS-CoV-2-specific humoral and cellular immunity in two renal transplants and two hemodialysis patients treated with convalescent plasma

회복기 혈장으로 치료받은 2명의 신장 이식 및 2명의 혈액투석 환자에서 SARS-CoV-2 특이 체액성 및 세포성 면역

Case Reports

Published on 2021-05-012022-09-11
Journal: Journal of medical virology [Category] MERS, SARS, 진단, 치료제,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 antibody Antibody titers antiviral drug antiviral immunity Antiviral treatment Case report cellular cellular immunity cellular response Cellular responses Chronic kidney disease Clinical improvement clinically close monitoring convalescent convalescent plasma coronavirus COVID-19 Day Deceased described discharged ELISA ELISPOT ELISpot responses enzyme enzyme-linked immunosorbent enzyme-linked immunosorbent assay Hemodialysis hospital humoral IgG immune response immune responses Immunoglobulin Immunoglobulin G interferon kidney Kidney disease kidney transplant kidney transplant recipient Kidney transplantation Neutralization assay neutralization titer Neutralizing antibody titer Patient patients treated Receptor-binding domain Remdesivir renal respiratory response S1 subunit SARS-CoV-2 SARS-CoV-2 spike protein SARS-CoV-2-specific antibodies SARS-CoV-2-specific antibody severe acute respiratory syndrome Coronavirus specific antibodies Spike protein the receptor-binding domain the S1 subunit the SARS-CoV-2 therapy Transplant Treatment treatment regimen typical symptom typical symptoms undetectable Viral Viral load were infected
[DOI] 10.1002/jmv.26840 PMC 바로가기 [Article Type] Case Reports

Reduced frequency of T helper 17 and T helper 1 cells and their association with critical coronavirus disease 2019

T 헬퍼 17 및 T 헬퍼 1 세포의 빈도 감소 및 중요한 코로나바이러스 질병 2019와의 연관성

Article

Published on 2021-05-012022-09-12
Journal: Apmis [Category] SARS, 진단,

Increased viral variants in children and young adults with impaired humoral immunity and persistent SARS-CoV-2 infection: A consecutive case series

체액성 면역 장애와 지속적인 SARS-CoV-2 감염이 있는 어린이 및 젊은 성인의 바이러스 변이체 증가: 연속 사례 시리즈

Multicenter Study

Published on 2021-05-012022-09-11
Journal: EBioMedicine [Category] MERS, SARS, 변종, 진단,

[키워드] accumulation Acute lymphoblastic leukemia Analysis broad spectrum Care Case report case sery Chain Reaction children evade Evidence evidence of highlight Host host immune responses Humoral immunity Immune escape immune responses Immunocompromised Immunocompromised patients Increased Infection infection control initial leukemia Lymphoblastic leukemia management Mutation mutations Patient pediatric performed persistent infection polymerase chain polymerase chain reaction positive Precaution real-time polymerase chain reaction Replication reservoir RNA routine SARS-CoV-2 Sequencing serological studies SEROLOGICAL STUDY single-stranded specimen strain subsequent Surveillance variants viability Viral viral culture viral evolution Viral transmission viral variant whole-genome sequencing
[DOI] 10.1016/j.ebiom.2021.103355 PMC 바로가기 [Article Type] Multicenter Study

Validation of a commercially available indirect assay for SARS-CoV-2 neutralising antibodies using a pseudotyped virus assay

유사형 바이러스 분석을 사용한 SARS-CoV-2 중화 항체에 대한 상업적으로 이용 가능한 간접 분석의 검증

Article

Published on 2021-05-012022-09-10
Journal: The Journal of Infection [Category] Fulltext, SARS, 진단, 치료기술, 치료제,

Genomic Evidence of SARS-CoV-2 Reinfection Involving E484K Spike Mutation, Brazil

E484K 스파이크 돌연변이와 관련된 SARS-CoV-2 재감염의 게놈 증거, 브라질

Case Reports

Published on 2021-05-012022-09-10
Journal: Emerging Infectious Diseases [Category] MERS, SARS, 변종, 유전자 메커니즘, 진단,

Treating exuberant, non-resolving inflammation in the lung; Implications for acute respiratory distress syndrome and COVID-19

폐의 무성하고 해결되지 않는 염증을 치료합니다. 급성호흡곤란증후군과 코로나19에 대한 시사점

Review

Published on 2021-05-012022-09-11
Journal: Pharmacology & therapeutics [Category] 임상,

[키워드] acute respiratory distress acute respiratory distress syndrome added aetiology age anti-inflammatory agent ARDS COVID-19 death driven by driving drug effective Efficacy elevated highlight Host immune response immune responses impairing increasing age Infection Inflammation inflammatory pathway inflammatory pathways Inflammatory response inhibit innate immune response lack likelihood lung; older patients p38 MAP kinase. pathogen Pathogens pathway Prevalence regimen respiratory distress Respiratory distress syndrome SARS-CoV-2 seasonal flu suggested susceptible syndrome the disease treating Treatment Vaccine vaccine efficacy while
[DOI] 10.1016/j.pharmthera.2020.107745 PMC 바로가기 [Article Type] Review

Convalescent plasma treatment of critically ill intensive care COVID-19 patients

중환자 중환자실 COVID-19 환자의 회복기 혈장 치료

Clinical Trial

Published on 2021-05-012022-09-11
Journal: Transfusion [Category] MERS, SARS, 비임상, 임상, 진단, 치료기술,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus All the patient all the patients antibody antiviral drug antiviral drugs antiviral immune response applied average breath Clinical outcome Complication convalescent plasma treatment coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patient COVID-19 patients Critically ill critically ill COVID-19 patients Deceased determined by died effective Efficacy eight enzyme enzyme-linked immunosorbent enzyme-linked immunosorbent assay Euroimmun FFP transfusion FIVE IgG IgG antibody immune responses Immunoglobulin Immunoglobulin G IMPROVE indicated Infectious disease infectious disease testing intensive care Intravenous immunoglobulin investigated life-threatening median multiple organ failure Neutralization assay Neutralizing titer neutralizing titers onset of symptoms organ Organ failure Patient patient survival patients plasma respiratory S1 protein SARS-CoV-2 SARS-CoV-2 RNA SARS-CoV-2-specific antibodies SARS-CoV-2-specific antibody sera Seven severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 specific antibodies survivor the S1 protein treated Treatment
[DOI] 10.1111/trf.16392 PMC 바로가기 [Article Type] Clinical Trial

Adaptive immune responses to SARS-CoV-2

SARS-CoV-2에 대한 적응 면역 반응

Review

Published on 2021-05-012022-09-12
Journal: Advanced drug delivery reviews [Category] MERS, SARS, 진단,

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial

비활성화된 SARS-CoV-2 백신 BBV152의 안전성 및 면역원성: 이중 맹검, 무작위, 1상 시험

Clinical Trial

Published on 2021-05-012022-09-11
Journal: The Lancet. Infectious Diseases [Category] Fulltext, SARS, 임상, 진단, 치료기술,

[키워드] 95% CI Administered adverse event Adverse reactions alum assigned baseline Bharat block Block randomisation CD4 CD8 Cell-mediated responses control group control vaccine COVID-19 doses double-blind Effect Efficacy eligible ELISPOT enrolled evaluated event fatigue Fever first dose groups headache healthy hospital immune responses immunogenicity inactivated India individual injection site pain intramuscular dose investigator investigators Local Mild mitigate moderate multicentre nausea neutralisation nine nucleic acid outcome participant Participants Phase 1 phase 1 trial Phase 2 platform Pneumonitis positive Primary outcomes randomisation randomised Randomly receive Registered reported response Safety SARS-CoV-2 nucleic acid SARS-CoV-2 vaccine screened secondary secondary outcome selected Serious Adverse Event Serious Adverse Events Seroconversion seroconversion rates serology test serology tests Seven staining study duration subset systemic adverse reaction systemic adverse reactions systemic reactogenicity T-cell Response T-cell responses the vaccine tolerable Toll-like receptor treatment group Trial trials vaccination Vaccine Viral vomiting was done were excluded wild-type virus
[DOI] 10.1016/S1473-3099(20)30942-7 PMC 바로가기 [Article Type] Clinical Trial